semaglutide menstrual irregularities Do GLP-1 weight loss drugs affect the cycle? Understanding the Impact of Weight

Come prepared to discuss your weight loss efforts and goals

Results: The 18-month risk for ION was 8.5 versus 5.5 per 10 000 among GLP-1RA users versus SGLT2i users (RD, 3.0 [95% CI, 0.4 to 5.7]) and 7.8 versus 4.2 per 10 000 among GLP-1RA users versus DPP4i users (RD, 3.6 [CI, 1.1 to 6.1])

However, different side effects have been reported in treated patients, including gastrointestinal effects such as nausea, diarrhea, vomiting, constipation, abdominal pain, and dyspepsia

Uninsured patients represent one of the fastest-growing populations seeking weight loss medication, driven by rising obesity rates and limited employer-sponsored coverage options

Higher blood sugar levels are linked to increased hunger, making simple calorie restriction difficult and even dangerous